Zymeworks Shifts To Royalty-Driven Model From Licensed Drugs, Approves $125M Buyback Plan

• The proceeds from the development and commercialization of Ziihera, Pasritamig, among others, will be reinvested in the company’s research and development, focusing on both internal and acquired product candidates.
• The company also added that its Board of Directors has authorized a new share repurchase plan under which the company may repurchase up to $125 million of its outstanding common stock. 
• The strategic decision follows the company's announcement of positive data from a trial evaluating Ziihera in combination with chemotherapy, with or without Tevimbra, as a first-line treatment for certain cases of gastroesophageal adenocarcinoma.

Shares of Zymeworks Inc. (ZYME) were in the limelight on Tuesday after the company announced that it plans to evolve into a royalty-focused business model centered on its licensed products going forward, a strategic pivot aimed at regulating future cash flow. 

“We have made the strategic decision to evolve from a traditional biotechnology company into a royalty-driven organization differentiated by in-house R&D capabilities,” said CEO Kenneth Galbraith. The strategy will combine internal innovation, licensing, and strategic acquisitions, the company said.

The company already has arrangements in place for its product portfolio, including Ziihera and Pasritamig. The proceeds from the development and commercialization of Ziihera, Pasritamig, and potentially other products will be reinvested in the company’s research and development efforts, focusing on both internal and acquired product candidates, the company stated. 

The decision to focus on royalty was made after a strategic review given significant future cash flows anticipated from Ziihera, Pasritamig, and other licensed products and product candidates, the company said. Under the strategy, the company also intends to return excess capital directly to shareholders via share repurchase programs or special dividends.

“We intend to fund our healthcare asset aggregation strategy through a combination of cash flows arising from current licensed assets along with the potential for external funding where it can be secured at a reasonable cost of capital,” the CEO added. The company also appointed Scott Platshon as Acting Chief Investment Officer to enable execution of the new initiative. 

The company now expects future partnerships and collaborations to play an important role in funding ongoing research and development investments, reducing reliance on its internal capital. 

Share Repurchase Plan

The company also added that its Board of Directors has authorized a new share repurchase plan under which the company may repurchase up to $125 million of its outstanding common stock. 

The company expects its cash resources as of the end of the third quarter, in addition to certain anticipated milestone payments, to fund planned operations beyond 2028.

Positive Trial Takeaways

The strategic decision follows the company's announcement of positive data from a trial evaluating Ziihera in combination with chemotherapy, with or without Tevimbra, as a first-line treatment for certain cases of gastroesophageal adenocarcinoma, including cancers of the stomach, gastroesophageal junction, and esophagus. 

Both Ziihera plus chemotherapy and Ziihera plus Tevimbra and chemotherapy demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared to trastuzumab plus chemotherapy, the company said on Monday. Ziihera plus Tevimbra and chemotherapy also demonstrated clinically meaningful and statistically significant improvements in overall survival, it added. 

Zymeworks’ partner Jazz now intends to submit a supplemental Biologics License Application in the first half of 2026 for the drug. 

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around ZYME jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels. 

ZYME stock is up 63% this year and approximately 60% over the past 12 months.

Read also: BTC Price Rebounds To $91,000 After $1 Billion Crypto Liquidation Wave

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on